LAUSANNE

Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Lunedì, Aprile 8, 2024
Inflammation, Pain, Patient, OCS

Dr. Donnenfeld presented the “Once Daily OCS-01, an OPTIREACH® Formulation of High Concentration Dexamethasone Eye Drop, for Inflammation and Pain Following Cataract Surgery – a Phase 3, Double-Masked, Vehicle-Controlled Study” on Sunday, April 7th.

Key Points: 
  • Dr. Donnenfeld presented the “Once Daily OCS-01, an OPTIREACH® Formulation of High Concentration Dexamethasone Eye Drop, for Inflammation and Pain Following Cataract Surgery – a Phase 3, Double-Masked, Vehicle-Controlled Study” on Sunday, April 7th.
  • The results showed that 57.2% of patients treated with OCS-01 were inflammation free (i.e.
  • absence of anterior chamber cells) at Day 15 (vs. 24.0% with vehicle, p
  • The two Phase 3 OPTIMIZE trials are expected to support an NDA submission.

Oculis to Participate at Upcoming April Investor Conferences

Retrieved on: 
Giovedì, Aprile 4, 2024
OCS, Cryptocurrency

ZUG, Switzerland and BOSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis’s management will be attending and presenting at the following upcoming investor conferences:

Key Points: 
  • ZUG, Switzerland and BOSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis’s management will be attending and presenting at the following upcoming investor conferences:
    The Company will be available for one-on-one meetings during the conferences.
  • Interested investors should contact their respective representative to request meetings.

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer

Retrieved on: 
Lunedì, Aprile 1, 2024
Novartis, Cardiovascular disease, Science, EPFL, Risk, Patient, NAMS, Harvard Business School, CBO, Partner, McKinsey & Company

“We are privileged to welcome Juliette to our management team as CBO,” said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam.

Key Points: 
  • “We are privileged to welcome Juliette to our management team as CBO,” said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam.
  • Prior to joining Forbion, Ms. Audet was a principal at the Novartis Venture Fund based in Cambridge, MA.
  • She also worked at Novartis AG for their commercial division and at McKinsey and Company focusing on Pharma and Biotech.
  • She earned her M.B.A. with distinction from Harvard Business School and her M.Sc.

Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress

Retrieved on: 
Lunedì, Marzo 18, 2024
Research, TNF, AON, Dexamethasone, Congress, International, International Financial Reporting Standards, Telecanthus, Inflammation, DME, Patient, SNP, NDA, American Academy, G&A, POC, Business analyst, IND, Abstract, DED, Bank statement, Genotype, Investment, Retina, Diabetic retinopathy, OCS, Safety, CHF, Pain, Stage 2, Pharmaceutical industry

Riad Sherif M.D., Chief Executive Officer of Oculis: “2023 was a remarkable milestone-rich year for Oculis.

Key Points: 
  • Riad Sherif M.D., Chief Executive Officer of Oculis: “2023 was a remarkable milestone-rich year for Oculis.
  • These non-IFRS financial measures exclude the impact of items that the Company’s management believes affect comparability or underlying business trends.
  • The Company’s management uses these measures to better analyze its financial results and better estimate its financial outlook.
  • The resulting non-cash foreign exchange impact of such reclassification amounted to CHF 5.0 million or $5.7 million for the year ended December 31, 2023.

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Giovedì, Marzo 14, 2024
University of Geneva, Diagnosis, Target, Down syndrome, MSA, Disease, ALS, PD, Safety, Multiple system atrophy, Patient, PET, Research, Geneva University Hospitals, Amyloid beta, MJFF, ABATE, Smith, University, KOL, Doctor of Philosophy, MD, TAR, IND, Medicine, AC, University of Luxembourg, Cognition, DS, Johnson & Johnson, Janssen, Sahlgrenska University Hospital, CHF, Injection, DSMB, University of Gothenburg, Food, RETAIN, Janssen Pharmaceuticals, Nature Communications, Pharmaceutical industry

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We made significant progress in 2023 advancing our three innovative active immunotherapy programs in Phase 2 clinical trials in Alzheimer’s and Parkinson’s diseases.

Key Points: 
  • Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We made significant progress in 2023 advancing our three innovative active immunotherapy programs in Phase 2 clinical trials in Alzheimer’s and Parkinson’s diseases.
  • Six-month Abeta positron emission tomography (PET) imaging results are expected in Q2 2024, and 12-month Abeta-PET data are expected in H2 2024.
  • Comm., 2023) showed that AC Immune’s wholly-owned a-syn-PET tracer ACI-12589 can detect a-syn pathology in multiple system atrophy (MSA) and differentiate MSA from other a-synucleinopathies.
  • PI-2620 was discovered and developed using the Morphomer® platform as part of a research collaboration between AC Immune and Life Molecular Imaging.

Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments

Retrieved on: 
Mercoledì, Febbraio 28, 2024
ASRS, Senior, Paris Diderot University, SAB, Reno 1868 FC, Growth, Visual acuity, University, DED, Telecanthus, Organization, Principal, Teaching hospital, Retina, Anthropology, Diabetic retinopathy, Therapy, OCS, Inflammation, CSO, DME, American Academy, Simmons University, M.A, Clinical research, ASCRS, Society, Cerebral edema, Eastern Virginia Medical School, Patient, Partner (business rank), Medicine, Pharmaceutical industry

In-person and virtual R&D Day today from 9:00 AM to 11:00 AM EST at the InterContinental New York Barclay.

Key Points: 
  • In-person and virtual R&D Day today from 9:00 AM to 11:00 AM EST at the InterContinental New York Barclay.
  • “2024 promises to be another exciting year for Oculis as we advance our late-stage clinical development programs.
  • I am certain that the extensive experience each of them brings will be invaluable to Oculis,” said Riad Sherif, M.D., Chief Executive Officer of Oculis.
  • Oculis also announced today key executive appointments to bolster its leadership and scientific advisory teams.

Pulsed Field Ablation Innovator Argá Medtech Announces €54 Million Oversubscribed Series B Capital Raise

Retrieved on: 
Martedì, Febbraio 27, 2024
SAN, PFA, Physician, Phrenic nerve, IDE, Arrhythmia, Risk, Medtech, Atrial fibrillation, Patient, Heart, Tissue, Esophagus

LAUSANNE, Switzerland and SAN DIEGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Argá Medtech, a private company developing Coherent Sine-Burst Electroporation™ (CSE™), a next-generation cardiac ablation system for treating cardiac arrhythmias, including atrial fibrillation (AF), today announced the closure of a €54M oversubscribed Series B funding. The round was led by the existing investors, Advent Life Sciences (UK) and Earlybird Health (Germany), as well as new investor Gilde Healthcare (the Netherlands) and an undisclosed strategic investor. The financing enables Argá Medtech to advance the development of its innovative CSE™ Pulsed Field Ablation (PFA) system for treating AF through the execution of an IDE study in the US and a CE Mark study in the EU. With the funding, the company will also expand its US offices in San Diego, CA, in anticipation of its US clinical activities.  

Key Points: 
  • The financing enables Argá Medtech to advance the development of its innovative CSE™ Pulsed Field Ablation (PFA) system for treating AF through the execution of an IDE study in the US and a CE Mark study in the EU.
  • With the funding, the company will also expand its US offices in San Diego, CA, in anticipation of its US clinical activities.
  • “We are pleased to secure the support of such marquee investors who believe that Argá Medtech will revolutionize the atrial fibrillation ablation field,” said David Neale, CEO of Argá Medtech.
  • Argá Medtech’s CSE™ system uses a sinusoidal/sine wave, while other PFA platforms are typically powered by square wave energy sources.

AC Immune Announces Upcoming Presentations at AD/PD™ 2024

Retrieved on: 
Giovedì, Febbraio 22, 2024
PD, Alpha-synuclein, Conference, Down syndrome, Medicine, Synucleinopathy, Diagnosis, Primate

Lausanne, Switzerland, February 22, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming presentations highlighting its precision medicine pipeline at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024), taking place in Lisbon, Portugal March 5-9, 2024.

Key Points: 
  • Lausanne, Switzerland, February 22, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming presentations highlighting its precision medicine pipeline at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024), taking place in Lisbon, Portugal March 5-9, 2024.
  • In addition, Andrea Pfeifer, Ph.D., CEO of AC Immune SA will lead an industry symposium exploring the latest clinical advances in the diagnosis and treatment of alpha-synuclein pathologies.
  • Active immunotherapy ACI-7104.056 in early PD: update from the Phase 2 trial VacSYn
    Utility of [18F]PI-2620 PET in clinical trials: insights into tau pathology deposition in Down Syndrome
    Discovery and preclinical development of [18F]ACI-19626, a first-in-class TDP-43 PET tracer
    VacSYn study: An innovative biomarker-based phase 2 clinical trial to evaluate ACI-7104.056, a novel active immunotherapy for Parkinson’s disease
    ACI-7104.056, an active immunotherapy for synucleinopathies, induces a strong and sustained antibody response against alpha-synuclein in non-human primates

Vandria Awarded €3.8M in Prestigious Innosuisse and Eurostars Grants to Advance Innovative Drug Programs for Age-Related Diseases of the CNS and Muscle

Retrieved on: 
Giovedì, Febbraio 8, 2024
Partnership, Mitophagy, CHF, Lead, European, Conditional sentence, Science, Research, Deficit spending, AP-HP, MD, Mitochondrion, Therapy, Myopathy, Lung, CNS, Dementia, NASH, Liver, Pharmaceutical industry

Vandria contributes CHF 4.6M to the grant alongside the CHF 2.5M non-dilutive funding from Innosuisse.

Key Points: 
  • Vandria contributes CHF 4.6M to the grant alongside the CHF 2.5M non-dilutive funding from Innosuisse.
  • Innosuisse is the Swiss Innovation Agency that helps to fund science-based pre-commercial projects of start-ups with significant innovation potential.
  • Klaus Dugi, MD, CEO of Vandria, said, “These prestigious grant awards are an endorsement of the science and the team behind Vandria.
  • The Eurostars grant significantly helps us to advance, in parallel, our program in muscle disease.

Oculis to Present at Upcoming February Investor Conferences

Retrieved on: 
Lunedì, Gennaio 29, 2024
OCS

ZUG, Switzerland and BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis’ management will be attending and presenting at the following upcoming investor conferences:

Key Points: 
  • ZUG, Switzerland and BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis’ management will be attending and presenting at the following upcoming investor conferences:
    Location: Hotel Sofitel Legend The Grand Amsterdam, Amsterdam, Netherlands
    The Company will be available for one-on-one meetings during the conferences.
  • Interested investors should contact their respective representative at the sponsoring institutions to request meetings.